To include your compound in the COVID-19 Resource Center, submit it here.

Bolt’s myeloid twist on ADCs charged up with $93.5M series C

Bolt’s innate immune-activating take on ADCs could bring durable antitumor activity to more patients

Bolt’s $93.5 million series C round will enable the Stanford spinout to clinically test whether its myeloid-activating antibody conjugate can provide durable treatment to a broad swath of HER2-positive solid tumor patients.

Led by Sofinnova Investments, the round also included new investors RA Capital Management, Surveyor Capital, Rock Springs Capital, Samsara BioCapital and Pfizer Ventures, along with existing investors including Novo Holdings, Vivo Capital, Pivotal bioVenture Partners.

Bolt Biotherapeutics Inc.’s immune-stimulating antibody conjugate (ISAC) platform is

Read the full 751 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE